Nanjing Well Pharmaceutical Co Ltd Net Assets
Nanjing Well Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) has net assets worth CN¥1.84 Billion CNY (≈ $269.38 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.63 Billion ≈ $384.59 Million USD) and total liabilities (CN¥787.30 Million ≈ $115.21 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Nanjing Well Pharmaceutical Co Ltd (603351) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.84 Billion |
| % of Total Assets | 70.04% |
| Annual Growth Rate | 20.1% |
| 5-Year Change | 30.13% |
| 10-Year Change | 306.06% |
| Growth Volatility | 28.16 |
Net Assets of Nanjing Well Pharmaceutical Co Ltd (2014–2025)
Net assets of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Nanjing Well Pharmaceutical Co Ltd (603351) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Nanjing Well Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual net assets of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2025. For live market cap and overall valuation, see Nanjing Well Pharmaceutical Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.80 Billion ≈ $263.81 Million |
+5.54% |
| 2024-12-31 | CN¥1.71 Billion ≈ $249.96 Million |
+7.25% |
| 2023-12-31 | CN¥1.59 Billion ≈ $233.06 Million |
+7.44% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.92 Million |
+7.00% |
| 2021-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
+6.60% |
| 2020-12-31 | CN¥1.30 Billion ≈ $190.18 Million |
+4.71% |
| 2019-12-31 | CN¥1.24 Billion ≈ $181.63 Million |
+101.95% |
| 2018-12-31 | CN¥614.61 Million ≈ $89.94 Million |
+15.36% |
| 2017-12-31 | CN¥532.80 Million ≈ $77.96 Million |
+20.00% |
| 2016-12-31 | CN¥443.99 Million ≈ $64.97 Million |
+50.76% |
| 2015-12-31 | CN¥294.49 Million ≈ $43.09 Million |
+22.52% |
| 2014-12-31 | CN¥240.35 Million ≈ $35.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Well Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 229.3% over the analyzed period, indicating profitable operations and earnings retention.
Nanjing Well Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Nanjing Well Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥652.49 Million | 36.34% |
| Other Components | CN¥1.14 Billion | 63.66% |
| Total Equity | CN¥1.80 Billion | 100.00% |
Nanjing Well Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Well Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LSI Industries Inc
NASDAQ:LYTS
|
$534.80 Million |
|
China Hi-Tech Group Co Ltd
SHG:600730
|
$534.82 Million |
|
Chularat Hospital Public Company Limited
BK:CHG
|
$534.86 Million |
|
Canadian Tire Corporation Limited
TO:CTC
|
$534.90 Million |
|
Hainan Haiqi Transportation Group Co Ltd
SHG:603069
|
$534.54 Million |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
$534.43 Million |
|
Ur Energy Inc
NYSE MKT:URG
|
$534.22 Million |
|
Ability Opto-Electronics Technology Co Ltd
TWO:3362
|
$534.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Well Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,701,923,864 to 1,795,462,891, a change of 93,539,027 (5.5%).
- Net income of 150,968,971 contributed positively to equity growth.
- Dividend payments of 64,888,779 reduced retained earnings.
- Other comprehensive income decreased equity by 67,884,173.
- Other factors increased equity by 75,343,008.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥150.97 Million | +8.41% |
| Dividends Paid | CN¥64.89 Million | -3.61% |
| Other Comprehensive Income | CN¥-67.88 Million | -3.78% |
| Other Changes | CN¥75.34 Million | +4.2% |
| Total Change | CN¥- | 5.50% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Well Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.41x to 2.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥4.21 | CN¥26.98 | x |
| 2015-12-31 | CN¥5.17 | CN¥26.98 | x |
| 2016-12-31 | CN¥5.48 | CN¥26.98 | x |
| 2017-12-31 | CN¥5.44 | CN¥26.98 | x |
| 2018-12-31 | CN¥6.28 | CN¥26.98 | x |
| 2019-12-31 | CN¥9.69 | CN¥26.98 | x |
| 2020-12-31 | CN¥9.96 | CN¥26.98 | x |
| 2021-12-31 | CN¥10.37 | CN¥26.98 | x |
| 2022-12-31 | CN¥11.06 | CN¥26.98 | x |
| 2023-12-31 | CN¥11.72 | CN¥26.98 | x |
| 2024-12-31 | CN¥12.55 | CN¥26.98 | x |
| 2025-12-31 | CN¥13.26 | CN¥26.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Well Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.41%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.31%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.44x
- Recent ROE (8.41%) is below the historical average (12.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 18.68% | 8.50% | 1.26x | 1.75x | CN¥20.83 Million |
| 2015 | 20.63% | 12.17% | 1.02x | 1.66x | CN¥31.26 Million |
| 2016 | 19.17% | 15.23% | 0.93x | 1.35x | CN¥40.67 Million |
| 2017 | 20.16% | 15.48% | 0.96x | 1.36x | CN¥54.15 Million |
| 2018 | 18.19% | 13.95% | 0.99x | 1.31x | CN¥50.35 Million |
| 2019 | 10.32% | 14.55% | 0.60x | 1.17x | CN¥3.99 Million |
| 2020 | 7.73% | 13.65% | 0.45x | 1.26x | CN¥-29.52 Million |
| 2021 | 7.33% | 9.73% | 0.57x | 1.33x | CN¥-36.90 Million |
| 2022 | 6.42% | 8.55% | 0.52x | 1.44x | CN¥-53.00 Million |
| 2023 | 7.08% | 9.71% | 0.51x | 1.44x | CN¥-46.24 Million |
| 2024 | 8.60% | 11.29% | 0.54x | 1.40x | CN¥-23.77 Million |
| 2025 | 8.41% | 11.31% | 0.51x | 1.44x | CN¥-28.58 Million |
Industry Comparison
This section compares Nanjing Well Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,035,280,030
- Average return on equity (ROE) among peers: 6.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Well Pharmaceutical Co Ltd (603351) | CN¥1.84 Billion | 18.68% | 0.43x | $534.72 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.84% | 3.77x | $485.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $363.11 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.74 Billion | 10.72% | 0.24x | $4.79 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $15.79 Billion | 12.81% | 0.52x | $2.70 Billion |
| Wedge Industrial Co Ltd (000534) | $596.67 Million | 0.77% | 0.03x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $14.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.59 Billion | 5.90% | 1.18x | $770.77 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $267.57 Million | 2.03% | 1.53x | $275.43 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $925.00 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.63 Billion | 7.16% | 0.55x | $3.01 Billion |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China and internationally. The company offers excipients for injection, oral, and topical applications; and active pharmaceutical ingredients (API), such as polidocanol and polyethylene glycol 3… Read more